Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cryomass Technologies Inc. (CRYM)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
1001 Bannock Street 80204
Denver, CO, US
Denver, CO, US
CEO
Christian Noel
Website
cryomass.com
IPO
2014-06-02
CIK 1533030 ISIN US22905K1051
Description
Cryomass Technologies Inc., established in 2011 and based in Denver, Colorado, specializes in the development, distribution, and commercialization of cryo-mechanical systems. These systems are specifically engineered for processing freshly harvested hemp, cannabis, and other premium botanical materials. The company rebranded to its current name in August 2021, having previously operated as Andina Gold Corp.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15.7K
Beta
-0.23
Float Shares
176.61M
Free Float %
74.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +19,900.00% | +0.00% | +19,900.00% | -60.00% | +0.00% | -99.27% | -99.76% | -99.88% | -99.98% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-102.23
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.6% Q3'24: +34.3% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-87,471.7% Q3'24: -7,789.2% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-92,569.4% Q3'24: -19,080.0% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'24: +60.6% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.0% Q3'24: +14.2% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.37× Q3'24: -0.90× (vs Q3'23)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.81M
OE per share TTM
-0.03
Owner's Yield
-2,871,929.97%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
600.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alexander Massa | 47.21M | 21.40% | — | 47.21M | — | 10.00 | IN | Canada | 2021-12-16 | ↗ |
| 2 | Hungry Asset Monster, Inc. | 46.10M | 21.00% | — | 46.10M | — | 10.00 | CO | Delaware | 2021-12-16 | ↗ |
| 3 | CRYM Co-Invest GP, LLC | 45.00M | 20.50% | — | 45.00M | — | 10.00 | OO | Delaware | 2021-12-16 | ↗ |
| 4 | CRYM Co-Invest LP | 45.00M | 20.50% | — | 45.00M | — | 10.00 | PN | Delaware | 2021-12-16 | ↗ |
| 5 | HAM Senior, Inc. | 1.10M | 0.60% | — | 1.10M | — | 10.00 | CO | Delaware | 2021-12-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
1.12
Neutral
Buys
4
Sells
2
Shares acquired
112.0K
Shares disposed
100.0K
Cash buys
2.00
Cash sales
—
Net activity
+12,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-14 | Noel Christian | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 0.03 | 1.0K | 8,625,632 | — | ↗ |
| 2023-09-29 | Mullin Philip Blair | Officer | M-Exempt | D | Stock Options | 50,000 | 0.16 | 8.0K | 1,900,000 | — | ↗ |
| 2023-09-26 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 10,334 | 0.09 | 919.73 | 1,002,400 | — | ↗ |
| 2023-07-20 | Mullin Philip Blair | Officer | M-Exempt | D | Stock Options | 50,000 | 0.16 | 8.0K | 1,950,000 | — | ↗ |
| 2023-05-19 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 30,000 | 0.09 | 2.8K | 940,400 | — | ↗ |
| 2023-05-18 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 20,000 | 0.09 | 1.9K | 940,400 | — | ↗ |
| 2023-05-16 | Radke Mark | Director | A-Award | A | Common Stock | 100,000 | 0.19 | 18.5K | 500,000 | — | ↗ |
| 2023-05-16 | Human Delon Hannes | Director | A-Award | A | Common Stock | 300,000 | 0.19 | 55.5K | 1,460,000 | — | ↗ |
| 2023-05-16 | Gobbo Mario | Director | A-Award | A | Common Stock | 100,000 | 0.19 | 18.5K | 500,000 | — | ↗ |
| 2023-05-03 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 14,500 | 0.09 | 1.3K | 890,400 | — | ↗ |
| 2023-05-01 | Noel Christian | Director / Officer | P-Purchase | A | Common Stock | 1,200 | 0.08 | 98.40 | 8,538,132 | — | ↗ |
| 2023-04-28 | Noel Christian | Director / Officer | P-Purchase | A | Common Stock | 14,000 | 0.10 | 1.4K | 8,486,932 | — | ↗ |
| 2023-01-11 | Noel Christian | Director / Officer | A-Award | A | Common Stock | 550,000 | 0.18 | 98.9K | 8,195,000 | — | ↗ |
| 2023-01-11 | Mullin Philip Blair | Officer | A-Award | A | Common Stock | 403,000 | 0.18 | 72.5K | 875,900 | — | ↗ |
| 2023-01-11 | Kovacevic Patricia Izabel | Officer | A-Award | A | Common Stock | 147,000 | 0.18 | 26.4K | 397,000 | — | ↗ |
| 2023-01-05 | Noel Christian | Officer | P-Purchase | A | Common Stock | 25,000 | 0.16 | 4.0K | 7,645,000 | — | ↗ |
| 2022-12-31 | Radke Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Mullin Philip Blair | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Kovacevic Patricia Izabel | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Human Delon Hannes | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Gobbo Mario | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-29 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 22,900 | 0.18 | 4.1K | 472,900 | — | ↗ |
| 2022-12-28 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 13,500 | 0.18 | 2.4K | 450,000 | — | ↗ |
| 2022-12-23 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 1,000 | 0.18 | 178.10 | 436,500 | — | ↗ |
| 2022-12-22 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 5,000 | 0.19 | 950.00 | 435,500 | — | ↗ |
| 2022-12-20 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 8,500 | 0.18 | 1.5K | 430,500 | — | ↗ |
| 2022-05-27 | Noel Christian | Officer | P-Purchase | A | Common Stock | 92,000 | 0.26 | 23.9K | 7,620,000 | — | ↗ |
| 2022-02-18 | Radke Mark | Director | A-Award | A | Common Stock | 200,000 | 0.65 | 130.0K | 200,000 | — | ↗ |
| 2022-02-18 | Noel Christian | Director / Officer | A-Award | A | Common Stock | 0 | 0.27 | — | 7,495,529 | — | ↗ |
| 2022-02-18 | Human Delon Hannes | Director | A-Award | A | Common Stock | 200,000 | 0.65 | 130.0K | 960,000 | — | ↗ |
| 2022-02-18 | Gobbo Mario | Director | A-Award | A | Common Stock | 200,000 | 0.65 | 130.0K | 200,000 | — | ↗ |
| 2022-01-12 | Noel Christian | Director / Officer | P-Purchase | A | Common Stock | 300,000 | 0.27 | 81.0K | 7,495,529 | — | ↗ |
| 2022-01-12 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 200,000 | 0.27 | 54.0K | 221,999 | — | ↗ |
| 2022-01-12 | Kovacevic Patricia Izabel | Officer | P-Purchase | A | Common Stock | 50,000 | 0.27 | 13.5K | 50,000 | — | ↗ |
| 2021-11-15 | Human Delon Hannes | Director | P-Purchase | A | Common Stock | 760,000 | 0.20 | 152.0K | 760,000 | — | ↗ |
| 2021-11-11 | Noel Christian | Director / Officer | P-Purchase | A | Warrant | 250,000 | 0.40 | 100.0K | 250,000 | — | ↗ |
| 2021-07-15 | Kovacevic Patricia Izabel | Officer | — | D | Stock Option | 1,000,000 | 0.29 | 290.0K | 0 | — | ↗ |
| 2021-07-13 | Kovacevic Patricia Izabel | Officer | A-Award | A | Stock Options | 1,000,000 | 0.29 | 290.0K | 1,000,000 | — | ↗ |
| 2021-05-06 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 5,000 | 0.17 | 825.00 | 21,999 | — | ↗ |
| 2021-05-04 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 2,000 | 0.18 | 359.00 | 16,999 | — | ↗ |
| 2021-04-28 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 5,000 | 0.18 | 875.00 | 11,999 | — | ↗ |
| 2021-04-19 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 999 | 0.19 | 189.81 | 6,999 | — | ↗ |
| 2021-04-15 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 1,000 | 0.20 | 199.30 | 2,006,000 | — | ↗ |
| 2021-04-09 | Mullin Philip Blair | Officer | P-Purchase | A | Common Stock | 5,000 | 0.19 | 950.00 | 2,005,000 | — | ↗ |
| 2021-04-01 | Noel Christian | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 6,000,000 | — | ↗ |
| 2020-10-29 | Mullin Philip Blair | Officer | A-Award | A | Stock Options | 2,000,000 | 0.16 | 320.0K | 2,000,000 | — | ↗ |
| 2020-10-29 | Human Delon Hannes | Director | A-Award | A | Stock Options | 1,500,000 | 0.16 | 240.0K | 1,500,000 | — | ↗ |
| 2020-04-07 | Mullin Philip Blair | Officer | — | D | Common Stock | 0 | 0.00 | — | 22,000 | — | ↗ |
| 2019-08-12 | Human Delon Hannes | Director | — | D | Common Stock | 0 | 0.00 | — | 760,000 | — | ↗ |
| 2019-07-25 | Radke Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-08 | Gobbo Mario | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-20.9K
Shares Outstanding
237.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christian Noel | Chief Executive Officer & Director | 457.7K | male |
| Philip Blair Mullin | Chief Financial Officer | 300.0K | male |
| Patricia I. Kovacevic | General Counsel, Corporate Secretary & Head of External Affairs | 266.2K | female |
| Caroline Lenardon | Consultant | — | female |
| Janice Matthews | Consultant | — | female |
| Ryan Smith | Chief Operating Officer of Good Meds | — | male |
| Stephen Schroeder | Consultant | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRYM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
